PHASE3
by Soundcraft Media
Latest episode
VAXXED: And the winner is... with OneVentures and Ose…
VAXXED: And the winner is... with OneVentures and Ose…
About this podcast
A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
Episodes
- VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics · 28 minModerna and BioNTech are getting all of the attention with their phase 3 clinical trials for lung cancer and melanoma. But someone else is already further ahead. French company…
- VAXXED: Game on, with BASE and WEHI · 26 minCancer vaccines are an area that anyone who is anyone is getting into, but it's a field led largely by academics, not-for–profits, and specialist researchers. So this week we go…
- VAXXED: Boom or bust? With Chris Kallos and Pitt Street Research · 19 minIn some ways, cancer vaccines are a history of hype and hope, over success. But that hasn't stopped people from trying. In 2024, biotech CEOs are hoping that this time, it's…
- VAXXED: Deadly infection, with Imugene and ImmVirX · 23 minCancer vaccines are a very niche section of cancer treatments. But two companies in Australia – the only two so far to go public with their work in this arena –are working on an…
- VAXXED: From Gardasil to mRNA, with Dr Ian Frazer and Wilsons Advisory · 29 minCancer vaccines started out as prevention. Think Gardasil for cervical and oral cancers caused by HPV, and the hepatitis B vaccine for liver cancer. But today the science has…
- NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek · 34 minDrone-deliveries of radioactive medicines and diagnostics to Australia's far-flung towns. Radiopharmaceuticals matched with genetic information to tailor precisely the right dose…
- NUKED: Patent puzzles, with FB Rice · 25 minThe rule of thumb in biotech is that it costs around $1 billion to bring a new therapy from lab to market. Protecting that investment is the patent system. But what if part of…
- NUKED: Australia the nuclear power, with entX and Cyclowest · 30 minCan Australia create a mine to lab to bedside production line for radiopharmaceutical medicine? It has the reactor, biotechs and the hospitals to do that last two, and even has a…
- NUKED: The IP game, with Clarity Pharmaceuticals and Radiopharm Theranostics · 26 minThe question we are dancing around in episode 3 of NUKED is whether locking down isotopes supply chains are really the only way to play the radiopharmaceutical game. We ask…
- NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals · 30 minIn early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was…
- NUKED: Why radiopharmaceuticals are exploding, with Peter MacCallum Cancer Centre and HB Biotechnology · 26 minThe radiopharmaceuticals sector is on a knife point. The scope of what nuclear medicine can do is exploding. But the radioisotopes that biotechs need to make those therapies are…
- The Silent Killer: The sci-fi episode, with Certa Therapeutics and University of Sydney CTC · 28 minWearable kidneys. Organs on a chip. Xenotransplantation. The future is here. But is that the future people in biotech are truly looking to? Because the future that Certa…
- The Silent Killer: Prevention is the next cure, with Kidney Health Australia and Proteomics International · 23 minWe may have led you on a bit in the first two episodes... kidney disease is still a big problem despite the massive shifts forward in treating it. There is a long way to go to…
- The Silent Killer: Who has the killer apps? With Dimerix and PYC Therapeutics · 25 minWe speak to Dimerix CEO Dr Nina Webster about why investors are thrilled with her company, as it nears the midway point for its Phase III clinical trial for the rare disease…
- The Silent Killer: Why biotechs are all in on kidney disease, with University of Sydney CTC and Chris Kallos · 27 minKidney disease is a silent killer, with only 10% of all people knowing they have it before damage has been done. But in the last five years there's been a surge of work that's…
- Phase III Trailer · 1 minLife sciences more than anywhere else is the successful mashup of money and tech. I'm Rachel Williamson and this is Phase III, a weekly podcast diving deep into Australian life…







